In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Femoral Artery Closure Roller Coaster

Executive Summary

Market share charts for femoral artery closure devices looked like a roller coaster through Q3 2000, with each quarter producing a new market leader--Datascope, St. Jude Medical, and Perclose. Interventional cardiologists, whose views on device utilization levels and product lines varied, helped explain the market share movements, among other things noting the introduction of smaller, six French devices that led to the success of St. Jude, with Angio-seal and Duet. Most physicians agreed that while experimentation with different devices at this early stage of the market's development was leading to strong sales for all products, most hospitals will, over time, reduce redundancy in the product line and likely will end up carrying only two brands.
Advertisement

Related Content

An Open Market for Vascular Access Closure Devices
The Redemption of St. Jude Medical

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel